Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-27T21:20:06.906Z Has data issue: false hasContentIssue false
  • English
  • Français

What Theories Are Tested in Clinical Trials?

Published online by Cambridge University Press:  01 January 2022

Spencer Phillips Hey
Get access Rights & Permissions [Opens in a new window]

Abstract

John Worrall and Nancy Cartwright have both argued that randomized controlled trials (RCTs) are “testing the wrong theory.” They claim that RCTs are designed to test inferences about the causal relationships in the study population, but this does not guarantee a justified inference about the causal relationships in the more diverse population in clinical practice. In this article I argue that the epistemology of theory testing in trials is more complicated than either Worrall’s or Cartwright’s accounts suggest. I illustrate this more complex theoretical structure with case studies in medical theory testing from Alzheimer’s research and anticancer drugs in personalized medicine.

Type
Medicine
Information
Philosophy of Science , Volume 82 , Issue 5 , December 2015 , pp. 1318 - 1329
Copyright
Copyright © The Philosophy of Science Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

†

This research received support under the PACEOMICS project, funded by Genome Canada, Genome Quebec, Genome Alberta, and the Canadian Institutes for Health Research (CIHR). I would like to thank Georgina Freeman, Jonathan Kimmelman, Julie Walsh, and the audience at the 2014 Philosophy of Science Association meeting for constructive feedback on the earlier drafts of this manuscript.

References

Belluck, Pam. 2012. “New Drug Trial Seeks to Stop Alzheimer’s before It Starts.” New York Times, May 15.Google Scholar
Cartwright, Nancy. 2007. “Are RCTs the Gold Standard?” BioSocieties 2 (1): 11–20.10.1017/S1745855207005029CrossRefGoogle Scholar
Cartwright, Nancy 2011. “The Art of Medicine: A Philosopher’s View of the Long Road from RCTs to Effectiveness.” Lancet 377:1400–1401.10.1016/S0140-6736(11)60563-1CrossRefGoogle Scholar
Friedman, Lawrence M., Furberg, Curt, and DeMets, David L.. 2010. Fundamentals of Clinical Trials. 3rd ed. New York: Springer.10.1007/978-1-4419-1586-3CrossRefGoogle Scholar
Golde, Todd E., Schneider, Lon S., and Koo, Edward H.. 2011. “Anti-aβ Therapeutics in Alzheimer’s Disease: The Need for a Paradigm Shift.” Neuron 69 (2): 203–13.10.1016/j.neuron.2011.01.002CrossRefGoogle ScholarPubMed
Hegi, Monika E., Diserens, Annie-Claire, Godard, Sophie, Dietrich, Pierre-Yves, Regli, Luca, Ostermann, Sandrine, Otten, Philippe, Melle, Guy Van, de Tribolet, Nicolas, and Stupp, Roger. 2004. “Clinical Trial Substantiates the Predictive Value of O-6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide.” Clinical Cancer Research 10 (6): 1871–74.10.1158/1078-0432.CCR-03-0384CrossRefGoogle ScholarPubMed
Hey, Spencer P., and Weijer, Charles. 2013. “Assay Sensitivity and the Epistemic Contexts of Clinical Trials.” Perspectives in Biology and Medicine 56 (1): 1–17.10.1353/pbm.2013.0002CrossRefGoogle ScholarPubMed
Joseph, Lawrence, Gyorkos, Theresa W., and Coupal, Louis. 1995. “Bayesian Estimation of Disease Prevalence and the Parameters of Diagnostic Tests in the Absence of a Gold Standard.” American Journal of Epidemiology 141 (3): 263–72.10.1093/oxfordjournals.aje.a117428CrossRefGoogle ScholarPubMed
Karran, Eric, Mercken, Marc, and de Strooper, Bart. 2011. “The Amyloid Cascade Hypothesis for Alzheimer’s Disease: An Appraisal for the Development of Therapeutics.” Nature Reviews Drug Discovery 10 (9): 698–712.10.1038/nrd3505CrossRefGoogle ScholarPubMed
Lalezari, Shadi, et al. 2013. “Combined Analysis of O6-methylguanine-DNA Methyltransferase Protein Expression and Promoter Methylation Provides Optimized Prognostication of Glioblastoma Outcome.” Neuro-oncology 15 (3): 370–81.10.1093/neuonc/nos308CrossRefGoogle ScholarPubMed
Lechapt-Zalcman, Emmanuèle, et al. 2012. “O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and Low MGMT-Encoded Protein Expression as Prognostic Markers in Glioblastoma Patients Treated with Biodegradable Carmustine Wafer Implants after Initial Surgery Followed by Radiotherapy with Concomitant and Adjuvant Temozolomide.” Cancer 118 (18): 4545–54.10.1002/cncr.27441CrossRefGoogle Scholar
Schwartz, Daniel, and Lellouch, Joseph. 1967. “Explanatory and Pragmatic Attitudes in Therapeutical Trials.” Journal of Chronic Diseases 20 (8): 637–48.10.1016/0021-9681(67)90041-0CrossRefGoogle ScholarPubMed
Shadish, William R., Cook, Thomas D., and Campbell, Donald T.. 2002. Experimental and Quasi-experimental Designs for Generalized Causal Inference. Boston: Houghton Mifflin.Google Scholar
Tunis, Sean R., Stryer, Daniel B., and Clancy, Carolyn M.. 2003. “Practical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in Clinical and Health Policy.” Journal of the American Medical Association 290 (12): 1624–32.Google ScholarPubMed
Worrall, John. 2010. “Evidence: Philosophy of Science Meets Medicine.” Journal of Evaluation in Clinical Practice 16:356–62.10.1111/j.1365-2753.2010.01400.xCrossRefGoogle ScholarPubMed